The fund, Sofinnova Crossover II, exceeded its original fundraising target, according to the investment firm. It is designed to provide growth capital to companies that have progressed beyond early-stage development and require substantial financing to advance clinical programmes and establish commercial operations.

The investment strategy will focus primarily on European clinical-stage biopharmaceutical and medical technology businesses, while allowing selective investments in the United States and other international markets.

Sofinnova expects the fund to support approximately 15 high-growth companies. Its initial portfolio already includes Hemab Therapeutics, CellCentric and Neurent Medical, reflecting an investment focus spanning different areas of healthcare innovation.

The fundraising highlights the importance of specialist investment capital in an industry where companies frequently require significant resources to move scientific discoveries through clinical trials, regulatory approval and commercial development.

Although Europe has developed a substantial biotechnology research base, emerging companies can face difficulties securing the financing required to compete internationally, particularly during the transition from clinical validation to commercial scale.

Crossover investment strategies seek to address this funding requirement by supporting businesses at a later stage of development, when scientific progress may be more established but substantial capital is still necessary.

Sofinnova said the fund was backed by the European Tech Champions Initiative, a fund-of-funds managed by the European Investment Fund.

The firm's previous crossover investments have included companies subsequently acquired by larger healthcare groups or listed publicly. These include LimFlow, Calliditas Therapeutics, Amolyt Pharma and Abivax, although previous outcomes do not guarantee similar returns from the new fund.

The latest fundraising also comes amid continued global competition for biotechnology investment, with European companies seeking to retain intellectual property, expand clinical programmes and build businesses capable of competing in international markets.

For the European life sciences sector, access to larger pools of specialist capital could strengthen the commercialisation pipeline and improve the prospects of scaling promising medical innovations.

The challenge will be translating scientific progress into successful clinical outcomes, regulatory approvals and sustainable commercial businesses.